Related Experiment Videos
How, when, and why to use apolipoprotein B in clinical practice
1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada. allan.sniderman@muhc.mcgill.ca
The American Journal of Cardiology
|November 7, 2002
Summary
Plasma apolipoprotein B (apo B) is a superior marker for coronary artery disease (CAD) risk and statin therapy effectiveness compared to LDL cholesterol. Apo B provides a more accurate assessment of cardiovascular risk in diverse patient groups.
Area of Science:
- Cardiovascular Medicine
- Clinical Chemistry
- Lipidology
Background:
- Plasma apolipoprotein B (apo B) is increasingly recognized as a superior biomarker for coronary artery disease (CAD) risk.
- Clinical risk is influenced by LDL particle number and the presence of small, dense LDL particles.
Purpose of the Study:
- To demonstrate the clinical utility of apo B measurement in practice.
- To highlight apo B's superiority over LDL cholesterol for CAD risk assessment and guiding statin therapy.
Main Methods:
- Review of evidence supporting apo B's efficacy over LDL cholesterol.
- Outline of biological mechanisms underlying apo B's predictive power.
- Presentation of clinical scenarios involving hypertriglyceridemic, hypercholesterolemic, and normolipidemic subjects.
Main Results:
- Apo B is a more accurate index of CAD risk than total or LDL cholesterol.
- Apo B effectively guides the adequacy of statin therapy.
- Laboratory measurement of apo B is standardized, precise, and cost-effective, unlike calculated LDL cholesterol which can underestimate true levels.
Conclusions:
- Apo B offers a more robust assessment of cardiovascular risk and therapeutic response.
- Routine use of apo B in diagnosing dyslipidemias and monitoring statin therapy is clinically justified.
- Methodological concerns regarding calculated LDL cholesterol underscore the need for apo B utilization.